The ROS1ders Interview Dr. Ross Camidge (16-May-2019)


On May 16, 2019, ROS1der co-founder Janet Freeman-Daily interviewed ROS1 expert D Ross Camidge, MD, PhD, Director of Thoracic Oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado in a Zoom Webinar. We discussed questions that have arisen among experienced patients in The ROS1ders regarding diagnosis, treatment, and research … Continue reading The ROS1ders Interview Dr. Ross Camidge (16-May-2019)

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC


Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada. This submission was led by … Continue reading pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Crizotinib approved for ROS1 in Australia


“From 1 January the medicine Xalkori® (crizotinib) will made available through the Pharmaceutical Benefits Scheme (PBS) for lung cancer patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. The drug may stop or slow the growth of Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer. Without the PBS subsidy the drug … Continue reading Crizotinib approved for ROS1 in Australia

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC


The new National Comprehensive Cancer Network (NCCN) Guidelines for non-small cell lung cancer (NSCLC) added lorlatinib as a ROS1 treatment option, after progression on crizotinib or ceritinib. This means most insurance should start covering lorlatinib for ROS1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (Version 2.2019) (subscription required, but … Continue reading NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC


“Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or … Continue reading U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC